Why the study?
Do changes in LDL and HDL particle subclasses with gemfibrozil therapy predict the reduction in new CHD events in men with low HDL cholesterol?
Population
1,061 men from the Veterans Affairs High-Density Lipoprotein Intervention Trial with low HDL cholesterol
Comparison
Gemfibrozil therapy vs Placebo
Design
Case-control
Follow-up
5.1-year (median)
Authors
Loading...
LDL/HDL particle counts may refine CHD risk prediction in low-HDL men; hypothesis-generating and requires prospective validation.
Do changes in LDL and HDL particle subclasses with gemfibrozil therapy predict the reduction in new CHD events in men with low HDL cholesterol?
Gemfibrozil favorably alters NMR-measured LDL and HDL particle subclasses, which independently predict the reduction in CHD events in men with low HDL cholesterol.
Otvos et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: